PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

Phase 1

Terminated

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: Placebo
Drug: Active

First Posted Date: 2023-10-26

Last Posted Date: 2025-04-23

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT06102174

Locations: 🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
Kaiser Permanente, Los Angeles, California, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 6 locations

A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India

Recruiting

Conditions: Transthyretin Amyloid Cardiomyopathy

Interventions: Drug: Tafamidis

First Posted Date: 2023-10-17

Last Posted Date: 2025-01-31

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT06086353

Locations: 🇮🇳
AIG Hospital, Hyderabad, India
🇮🇳
Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka, India

A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.

Recruiting

Conditions: COVID-19

Interventions: Other: Disease description
Drug: SoC

First Posted Date: 2023-10-17

Last Posted Date: 2024-01-19

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT06085924

Locations: 🇨🇳
Pfizer Limited, Taipei, Taiwan

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Completed

Conditions: Breast Cancer

Interventions: Drug: Palbociclib
Drug: Aromatase Inhibitor

First Posted Date: 2023-10-17

Last Posted Date: 2024-05-16

Lead Sponsor: Pfizer

Target Recruit Count: 779

Registration Number: NCT06086340

Locations: 🇺🇸
Pfizer New York, New York, New York, United States

A Study to Learn About the Study Medicine - Precedex in Children From Japan.

Active, not recruiting

Conditions: Sedation

Interventions: Drug: Dexmedetomidine Hydrochloride

First Posted Date: 2023-10-17

Last Posted Date: 2025-02-14

Lead Sponsor: Pfizer

Target Recruit Count: 110

Registration Number: NCT06085573

Locations: 🇯🇵
Pfizer, Toykyo, Japan

A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection

Phase 2

Terminated

Conditions: Respiratory Syncytial Virus Infection

Interventions: Drug: Placebo
Drug: Sisunatovir

First Posted Date: 2023-10-12

Last Posted Date: 2025-05-21

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT06079320

Locations: 🇺🇸
National Institute of Clinical Research, Westminster, California, United States
🇺🇸
Adult Medicine of Lake County, Inc., Mount Dora, Florida, United States
🇺🇸
Adult Medicine of Lake County, Mount Dora, Florida, United States

and more 15 locations

A Study to Learn About ABRYSVO Vaccine in Older Adults to Prevent Severe Respiratory Syncytial Virus (RSV) Disease

Active, not recruiting

Conditions: Respiratory Syncytial Viruses

Interventions: Biological: Prior standard of care receipt of Pfizer's ABRYSVO vaccine

First Posted Date: 2023-10-11

Last Posted Date: 2025-05-31

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT06077968

Locations: 🇺🇸
Pfizer, New York, New York, United States

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

Phase 3

Recruiting

Conditions: Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo

Interventions: Drug: Ritlecitinib
Drug: Placebo

First Posted Date: 2023-10-10

Last Posted Date: 2024-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 1450

Registration Number: NCT06072183

Locations: 🇺🇸
FXM Clinical Research - Miramar, Miramar, Florida, United States
🇺🇸
GCP Research, Global Clinical professionals, Saint Petersburg, Florida, United States
🇺🇸
USF Health, Tampa, Florida, United States

and more 227 locations

A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.

Withdrawn

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: dacomitnib

First Posted Date: 2023-10-10

Last Posted Date: 2025-02-07

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT06075615

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Novel hormonal therapy

First Posted Date: 2023-10-10

Last Posted Date: 2025-05-08

Lead Sponsor: Pfizer

Target Recruit Count: 3017

Registration Number: NCT06072196

Locations: 🇺🇸
Pfizer Inc, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy